MT-601, Marker's lead MAR-T cell therapy, is being evaluated in the nationwide multicenter Phase 1 APOLLO study ( clinicaltrials.gov identifier: NCT05798897) in patients with anti-CD19 CAR-T relapsed ...

Expanded CloudFirst platform in 2024 with 4 new Tier III data centers (UK & Chicago), totaling 10 globally to enhance multi-cloud and continuity services across North America and Europe Completed ...